AVR PIN Spółka z Ograniczoną Odpowiedzialnością (KRS 0000907939, NIP 5170417428) is a Polish company, headquartered in Rzeszów, Podkarpackie voivodeship. AVR PIN operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since June 24, 2021. AVR PIN's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - AVR PIN
Identity
- Name
- AVR PIN Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 24, 2021
- Registry status as of
- November 20, 2025
- Latest entry
- July 21, 2025
- Founding act
- 02.06.2021 R., REP. A NR 2842/2021, KANCELARIA NOTARIALNA W POZNANIU ALEJA WIELKOPOLSKA 28, 60-608 POZNAŃ, PRZED ZASTĘPC…
Articles of association history (1)
- June 2, 2021: 02.06.2021 R., REP. A NR 2842/2021, KANCELARIA NOTARIALNA W POZNANIU ALEJA WIELKOPOLSKA 28, 60-608 POZNAŃ, PRZED ZASTĘPCĄ NOTARIALNYM MICHAŁEM TOMASZKIEWICZEM,
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- PL. JANA KILIŃSKIEGO, 2, 35-005, RZESZÓW, POLSKA
- Voivodeship
- PODKARPACKIE
- District
- RZESZÓW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - AVR PIN
Credibility rating
31.2 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
48
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/5 yrs
Board changes
0
0/5 yrs
PKD changes
0
0/5 yrs
Name changes
0
0/5 yrs
Data from 5 years of registry activity.
Credibility history
Payment reliability score from 2021–2024
Current: E (31/100)
Trend: stable (-1.8 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2021–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - AVR PIN
Founded
June 24, 2021
5 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
RZESZÓW
PODKARPACKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
14.0 K PLN
280 shares total
Shareholders
3
shareholders
Board
1 person
Filed years
4 years
2021–2024 · profitable: 0/4
Registry entries
16
latest: July 21, 2025
Risk signals
Revenue
0 PLN
2024
Net profit
-10.1 K PLN
2024
Assets
102.0 K PLN
2024
Equity
22.4 K PLN
2024
EBITDA
N/A
2024
no depreciation data
Valuation
54.3 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - AVR PIN.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
